Skip to main content
Premium Trial:

Request an Annual Quote

Daniel O Shannessy, W. Thomas Amick, David Ferrick, Bernard Kasten, Pamela Kirby, Max Link, Laurence Jay Korn

Premium

Targeted Diagnostics & Therapeutics has hired Gen-Probe strategic planning director Daniel O’Shannessy as chief operating officer. O’Shannessy will “spearhead the next phase of clinical and business expansion” for TDT’s colorectal cancer diagnostics, imaging, and therapeutics, the company said. He will also oversee new products and technologies at the company.

Before taking a stint at San Diego-based Gen-Probe, O’Shannessy was chief scientific officer at Fujirebio Diagnostics, of Malvern, Pa. He received a BSc in biochemistry from the University of Queensland, Australia, and a PhD in biochemistry from the University of Auckland, New Zealand.


W. Thomas Amick has been appointed to the advisory board of Quaker Bioventures. Quaker, a venture capital firm based in Philadelphia, focuses on investments in life sciences companies in the US Mid-Atlantic region. Amick had a 30-year career as an executive with Johnson & Johnson. He was most recently vice president of J&J Development Corporation, and also was president of Jannsen-Ortho and Ortho Biotech Europe, as well as vice president of the company’s oncology franchise.


David Ferrick has joined Guava Technologies as vice president of biology and clinical applications. Ferrick previously was CEO and director of Sagres Discovery of Davis, Calif., a company he co-founded in 1999. Prior to joining Sagres, he was director of molecular and cellular biology at Rigel Pharmaceuticals in South San Francisco, Calif. He was also an associate professor of pathology, microbiology, and immunology at the University of California, Davis. Ferrick holds a PhD in immunology from Georgetown University. Guava is based in Hayward, Calif.


Bernard Kasten has been named CEO of SIGA Technologies. Previously Kasten was vice president of medical affairs of the MedPlus subsidiary of Quest Diagnostics. Kasten, a member of SIGA’s board of directors since May 2003, is a graduate of the Ohio State University College of Medicine.


Pamela Kirby has been named to the board of directors of Oscient Pharmaceuticals. Kirby was most recently CEO of Quintiles Transnational Corporation, which develops product development and commercialization strategies for the pharmaceutical and biotechnology industries. She previously was director of global pharmaceutical strategic marketing and product life cycle management for F. Hoffman-La Roche, and commercial director at British Biotech, which is now Vernalis. She was also vice president of corporate strategy, marketing, and business development at Astra, now AstraZeneca.


Max Link, a director of Protein Design Labs since 1993, has been elected chairman of the board, the company said June 30. He succeeds Laurence Jay Korn, who had been chairman of the board of the Fremont, Calif., company since 1987, the company said last week.

Link was CEO of Boehringer Mannheim-Therapeutics between 1993 and 1994, and also CEO of Cornage, of which Boehringer Mannheim-Therapeutics was the pharmaceutical division.

He also was the chairman of Sandoz between 1992 and 1993, after holding various positions there since 1971.

Filed under